Table S5 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

作者：Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada, Sanam Loghavi, Koji Sasaki, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Akhil Jain, Mikaela McCabe, Fadi Haddad, Mark Brandt, Guilin Tang, Yesid Alvarado, Kayla Farish, Hussein A. Abbas, Guillermo Garcia‐Manero, Farhad Ravandi, Michael Andreeff, Gautam Borthakur · 年份：2026 · DOI：10.1158/2643-3230.32845791 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Eosinophilic Disorders and Syndromes

<p>Baseline characteristics and outcomes of patients with a pathogenic KIT mutation with VAF>5%</p>